BJA

British Journal of Anaesthesia, 123 (6): 916 (2019)

doi: 10.1016/j.bja.2019.09.003
Advance Access Publication Date: 18 September 2019
Corrigendum

CORRIGENDUM

Corrigendum to 'Spinal $GABA_A$ receptors for pain control: back to the future?' (*Br J Anaesth* 2019; 123: e176-9)

Hanns U. Zeilhofer[1,2,3,*], Elena Neumann[1] and Gordon Munro[4]

[1]Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland, [2]Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology (ETH) Zurich, Zurich, Switzerland, [3]Drug Discovery Network Zurich, Zurich, Switzerland and [4]Department of Neurology, Danish Headache Center, Glostrup Research Institute, Glostrup, Denmark

*Corresponding author. E-mail: Zeilhofer@pharma.uzh.ch
DOI of original article: https://doi.org/10.1016/j.bja.2019.01.030.

The authors and the publisher regret that a reference was omitted from the above article. The fourth sentence of the opening paragraph should read as follows

The compound PF-06372865, the subject of a study by van Amerongen and colleagues[1] in a recent issue of the British Journal of Anaesthesia, was developed by Pfizer Inc (Cambridge, UK) as a partial agonist at the benzodiazepine binding sites of receptors containing α2, α3, or α5 subunits.[2]

Reference 1 and 2, as cited in this sentence, should have been listed as:

1. van Amerongen G, Siebenga PS, Gurrell R, *et al*. Analgesic potential of PF-06372865, an α2/α3/α5 subtype-selective $GABA_A$ partial agonist, in humans. Br J Anaesth 2019; 123: e194 - e203.

2. Nickolls SA, Gurrell R, van Amerongen G, *et al*. Pharmacology in translation: the preclinical and early clinical profile of the novel α2/3 functionally selective $GABA_A$ receptor positive allosteric modulator PF-06372865. Br J Pharmacol 2018; 175: 708-25.

Subsequent references to Nickolls and colleagues in the text relate to reference 2 above, which is listed as reference 1 in the original article.

The authors and the publisher would like to apologise for any inconvenience caused.